dc.contributor.author | Matts, Robert L. | |
dc.contributor.author | Dixit, Anshuman | |
dc.contributor.author | Peterson, Laura B. | |
dc.contributor.author | Sun, Liang | |
dc.contributor.author | Voruganti, Sudhakar | |
dc.contributor.author | Kalyanaraman, Palgunan | |
dc.contributor.author | Hartson, Steve D. | |
dc.contributor.author | Verkhivker, Gennady M. | |
dc.contributor.author | Blagg, Brian S. J. | |
dc.date.accessioned | 2017-03-30T17:49:33Z | |
dc.date.available | 2017-03-30T17:49:33Z | |
dc.date.issued | 2011-08-19 | |
dc.identifier.citation | Matts, R. L., Dixit, A., Peterson, L. B., Sun, L., Voruganti, S., Kalyanaraman, P., … Blagg, B. S. J. (2011). Elucidation of the Hsp90 C-terminal Inhibitor Binding Site. ACS Chemical Biology, 6(8), 800–807. http://doi.org/10.1021/cb200052x | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/23521 | |
dc.description.abstract | The Hsp90 chaperone machine is required for the folding, activation and/or stabilization of more than 50 proteins directly related to malignant progression. Hsp90 contains small molecule binding sites at both its N- and C-terminal domains, however, limited structural and biochemical data regarding the C-terminal binding site is available. In this report, the small molecule binding site in
the Hsp90 C-terminal domain was revealed by protease fingerprinting and photoaffinity labeling utilizing LC-MS/MS. The identified site was characterized by generation of a homology model for hHsp90α using the SAXS open structure of HtpG and docking the bioactive conformation of NB into the generated model. The resulting model for the bioactive conformation of NB bound to Hsp90α is presented herein. | en_US |
dc.publisher | ACS Chem Biol. | en_US |
dc.rights | Copyright © 2011 American Chemical Society | en_US |
dc.title | Elucidation of the Hsp90 C-terminal Inhibitor Binding Site | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Dixit, Anshuman | |
kusw.kuauthor | Peterson, Laura B. | |
kusw.kuauthor | Blagg, Brian S. J. | |
kusw.kudepartment | Biochemistry and Molecular Biology | en_US |
kusw.kudepartment | Medicinal Chemistry | en_US |
kusw.oanotes | Per Sherpa Romeo on 03/30/2017: Author's Pre-print: grey tick subject to Restrictions below, author can archive pre-print (ie pre-refereeing) Restrictions: Must obtain written permission from Editor Must not violate ACS ethical Guidelines Author's Post-print: grey tick subject to Restrictions below, author can archive post-print (ie final draft post-refereeing) Restrictions: If mandated by funding agency or employer/ institution If mandated to deposit before 12 months, must obtain waiver from Institution/Funding agency or use AuthorChoice 12 months embargo Publisher's Version/PDF: cross author cannot archive publisher's version/PDF General Conditions: On author's personal website, pre-print servers, institutional website, institutional repositories or subject repositories Non-Commercial Must be accompanied by set statement (see policy) Must link to publisher version Publisher's version/PDF cannot be used | en_US |
dc.identifier.doi | 10.1021/cb200052x | en_US |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.rights.accessrights | openAccess | |